Clinical trial

The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance Imaging

Name
k(2018)44
Description
Intracranial atherosclerotic disease is the most common cause of ischemic stroke that is directly attributed to the progression or rupture of intracranial high-risk plaque in Asia. Many studies mainly from Euro-American population with a focus on extracranial carotid plaque have fully demonstrated the advantages of intensive statin therapy on stabilizing or reversing plaque burden, reversing plaque composition presenting that lipid-rich necrotic core (LRNC) is gradually replaced by fibrous tissue, and even reversing pattern of arterial remodeling to reduce the occurrence of cerebrovascular events. Yet, direct evidence of the effect of intensive statin therapy on intracranial atherosclerotic plaques is lacking and the effect of statin intensity and duration on intracranial plaque burden and composition is still unclear. High resolution magnetic resonance imaging (HRMRI) is a new and non-invasive technique that enable to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery. Based on above discussion, the investigators conduct this study to further determine the effect of intensive statin in ischemic stroke with intracranial atherosclerotic plaques.
Trial arms
Trial start
2018-12-01
Estimated PCD
2024-11-30
Trial end
2024-11-30
Status
Recruiting
Phase
Early phase I
Treatment
Atorvastatin Calcium
20mg Qd for 12 months
Arms:
Routine-dose statin group
Atorvastatin Calcium
40-80mg Qd for 6 months
Arms:
high-dose statin or PCSK9 inhibitor group
Probucol
0.5g Bid for 6 months
Arms:
high-dose statin or PCSK9 inhibitor group
PCSK9 inhibitor
Evolocumab 140mg subcutaneously injected, twice each month
Arms:
high-dose statin or PCSK9 inhibitor group
Size
100
Primary endpoint
Changes in remodeling index after the statin treatment
baseline, 6 months, 12 months after treatment
Changes in plaque burden after the statin treatment
baseline, 6 months, 12 months after treatment
Changes plaque composition in after the statin treatment
baseline, 6 months, 12 months after treatment
Eligibility criteria
Inclusion Criteria: 1. Patient age between 18-80 years 2. Time of onset: within 1 week 3. NIHSS score ≤12 4. Acute ischemic stroke confirmed by head CT or MRI 5. Premorbid mRS ≤1 6. The degree of stenosis of carotid artery, vertebral artery and intracranial portion of internal carotid artery on the lesion side \<50% 7. The culprit plaque or possible culprit plaque with plaque burden of 40% or more found by HRMRI in the proximal part of the middle cerebral artery M1 segment or basilar artery of ipsilateral lesion 8. Signed informed consent Exclusion Criteria: 1. Intracranial hemorrhage found by head CT 2. Stroke attributable to cardioembolic origin (atrial fibrillation, valvular heart disease, aortic arch atherosclerosis) 3. Severe hepatic or renal dysfunction 4. Pregnant females 5. Abnormal elevation of creatine phosphokinase 6. Expected stent angioplasty 7. Blood sugar is out of control 8. Receiving statins within 1 month before onset 9. Obstinate hypertension with more than 140/90 mmHg after medication 10. Not willing and able to comply with scheduled visits, lifestyle guidelines, treatment plan, laboratory tests, and other study procedures 11. Unsuitable for this clinical studies assessed by researcher
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2024-02-23

1 organization

3 products

4 indications

Indication
stroke
Indication
Ischemic
Indication
Atherosclerosis
Indication
Cerebral
Product
Probucol